ストックスクリーナーアプリを入手
34.90
1.41%
-0.4971
前日終値:
$35.40
開ける：
$35.62
24時間の取引高:
194.59K
Relative Volume:
0.12
時価総額：
$5.17B
収益：
$813.46M
当期純損益:
$-365.74M
株価収益率:
-12.16
EPS:
-2.87
ネットキャッシュフロー:
$-375.18M
1週間 パフォーマンス:
-6.25%
1か月 パフォーマンス:
-10.51%
6か月 パフォーマンス:
-6.61%
1年 パフォーマンス:
-28.83%
1日の値動き範囲:
$34.83
$35.65
1週間の範囲:
$33.33
$37.29
52週間の値動き範囲:
$33.33
$54.44
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
名前
Ionis Pharmaceuticals Inc
セクター
電話
(760) 931-9200
住所
2855 GAZELLE COURT, CARLSBAD, CA
IONS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| IONS | 34.92 | 5.17B | 813.46M | -365.74M | -375.18M | -2.87 |
| VRTX | 447.70 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.19 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.22 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-10-23 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 開始されました | Raymond James | Strong Buy |
| 2023-07-31 | アップグレード | Citigroup | Neutral → Buy |
| 2023-06-07 | 再開されました | Piper Sandler | Overweight |
| 2023-05-04 | アップグレード | Citigroup | Sell → Neutral |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2022-12-21 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 再開されました | Morgan Stanley | Overweight |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-31 | 再開されました | Piper Sandler | Overweight |
| 2022-03-01 | 開始されました | Citigroup | Sell |
| 2022-03-01 | 開始されました | Guggenheim | Buy |
| 2022-02-01 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-14 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | アップグレード | UBS | Sell → Neutral |
| 2021-03-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 開始されました | UBS | Sell |
| 2020-12-15 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-09-14 | 再開されました | JP Morgan | Neutral |
| 2020-09-02 | 開始されました | The Benchmark Company | Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-13 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-11-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 繰り返されました | Stifel | Hold |
| 2018-08-07 | 繰り返されました | Stifel | Hold |
| 2018-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 再開されました | Goldman | Sell |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-08-09 | 繰り返されました | Stifel | Hold |
| 2017-03-10 | ダウングレード | Goldman | Neutral → Sell |
| 2016-12-28 | 繰り返されました | BMO Capital Markets | Outperform |
| 2016-12-27 | 繰り返されました | Leerink Partners | Mkt Perform |
すべてを表示
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Transthyretin Amyloidosis Treatment Market Top PlayersIonis - openPR
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angel - GuruFocus.com
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Ionis reaches agreement on phase 3 trial design for Angelman candidate - MSN
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now - MSN
Familial Chylomicronemia Syndrome Market Expected - openPR
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks - Yahoo Finance
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Sees Large Increase in Short Interest - MarketBeat
RSI Alert: Ionis Pharmaceuticals (IONS) Now Oversold - Nasdaq
BB Biotech AG Adjusts Stake in Ionis Pharmaceuticals - GuruFocus.com
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 1-Year Low on Insider Selling - MarketBeat
Insider Sale: CEO Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus.com
Ionis Pharmaceuticals EVP Eric Swayze sells shares worth $45,277 - Investing.com
Ionis Pharmaceuticals director Joseph Loscalzo sells shares for $511,426 - Investing.com
Ionis Pharmaceuticals CEO Brett Monia sells $252,294 in stock - Investing.com
T. Rowe Price Investment Management, Inc. Expands Stake in Ionis Pharmaceuticals Inc - GuruFocus.com
Piper Sandler Issues Pessimistic Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer - cnhinews.com
Baillie Gifford & Co. Sells 220,673 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals' SWOT analysis: RNA pioneer's stock faces pivotal year - Investing.com
Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma - The Globe and Mail
Acromegaly Market Forecasted to Surge in Coming Years, - openPR
StockNews.com Downgrades Ionis Pharmaceuticals (NASDAQ:IONS) to Sell - MarketBeat
What is Leerink Partnrs' Forecast for IONS FY2024 Earnings? - MarketBeat
Wellington Management Group LLP Increases Stake in Ionis Pharmac - GuruFocus.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2024 Earnings Call Transcript - Insider Monkey
FY2028 EPS Estimates for IONS Reduced by Leerink Partnrs - MarketBeat
ARK Investment Management LLC Buys 23,244 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus - MSN
Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Ionis to present at upcoming investor conferences - GuruFocus.com
FDA agrees to review Ionis’ donidalorsen as treatment for HAE - Angioedema News Today
Is there a 2024 Duloxetine recall? FDA flags 7,100+ bottles of generic Cymbalta antidepressants - AOL
Bristol Myers wins US FDA approval for new type of schizophrenia drug - AOL
Why Walgreens, CVS and Rite Aid are closing thousands of drug stores across America - AOL
Needham & Company LLC Reaffirms Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - MarketBeat
EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts - AOL
Ionis to present at upcoming investor conferences – Company Announcement - Financial Times
Ionis announces design for Phase III trial of Angelman syndrome therapy - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... - Yahoo Finance
Ionis Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Ionis Looks Ahead To Commercializing Its Own Products - Citeline News & Insights
Ionis Pharmaceuticals Beats on Revenue - The Motley Fool
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings: Revenue Surpa - GuruFocus.com
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? - The Motley Fool
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) 財務データ
収益
当期純利益
現金流量
EPS
Ionis Pharmaceuticals Inc (IONS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Monia Brett P | Chief Executive Officer |
Nov 12 '24 |
Sale |
38.05 |
6,630 |
252,294 |
167,393 |
| LOSCALZO JOSEPH | Director |
Nov 12 '24 |
Sale |
37.86 |
13,508 |
511,426 |
32,251 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):